Clinical Trials Browser

Anastrozole × Breast × 90 days × Clear all

NCT05780567 2026-04-17

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT07174336 2026-04-17

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Recruiting

Anatomic Stage III Breast Cancer AJCC v8

NCT02095184 2026-04-15

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

Phase NA Terminated

42 enrolled 13 charts

Breast Neoplasms

NCT04852887 2026-04-15

DEBRA

Phase 3 Recruiting

Breast Neoplasms

NCT01127295 2026-04-14

PHACS

Phase 4 Completed

Breast Neoplasms

NCT01553903 2026-04-14

OXYTAM

Phase 4 Completed

Breast Neoplasms

NCT01612871 2026-04-14

MIRHO

Phase 4 Completed

Breast Neoplasms

NCT06380751 2026-04-14

EvoPAR-BR01

Phase 3 Recruiting

Advanced Breast Cancer

NCT00310180 2026-04-13

TAILORx

Phase 3 Active not recruiting

10,273 enrolled 14 charts

Breast Neoplasms

NCT01272037 2026-04-13

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Phase 3 Active not recruiting

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT05774951 2026-04-13

CAMBRIA-1

Phase 3 Recruiting

Breast Neoplasms

NCT05837455 2026-04-13

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07391774 2026-04-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Phase 3 Not yet recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Phase 2 Recruiting

Breast Neoplasms

NCT05467891 2026-04-08

RaPhLRR

Phase 2 Recruiting

Locoregional Recurrence

NCT04569747 2026-04-02

ADEPT

Phase 2 Active not recruiting

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

Phase 3 Active not recruiting

Breast Neoplasms

NCT06905301 2026-04-01

IMPULSE

Breast Neoplasms

NCT05307705 2026-03-27

PIKASSO-01

Phase 1 Active not recruiting

Breast Neoplasms

NCT06492616 2026-03-27

ELEGANT

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT00893061 2026-03-17

MNEMOSYNE

Phase 3 Completed

Breast Neoplasms

NCT06075953 2026-03-16

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Phase 2 Recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT06930859 2026-03-16

ELEGANCE

Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

Phase 3 Recruiting

Breast Neoplasms

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT05524584 2026-03-11

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06671912 2026-03-04

LoTam

Phase 3 Suspended

Breast Carcinoma In Situ

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

Breast Neoplasms

NCT07225790 2026-02-27

Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases

Advanced Breast Cancer

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Active not recruiting

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

NCT05896566 2026-02-24

PREcoopERA

Phase 2 Completed

Breast Neoplasms

NCT06507618 2026-02-24

POWER II

Phase 3 Recruiting

Breast Neoplasms

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast Neoplasms

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02763566 2026-02-05

MONARCH plus

Phase 3 Active not recruiting

463 enrolled 20 charts

Breast Neoplasms

NCT02246621 2026-02-03

MONARCH 3

Phase 3 Active not recruiting

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT03616587 2026-01-28

SERENA-1

Phase 1 Active not recruiting

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

Breast Neoplasms

NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07024173 2026-01-26

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT01953588 2026-01-22

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Phase 3 Active not recruiting

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Phase 3 Recruiting

Breast Neoplasms